"The Trump administration negotiated lower prices for weight-loss drugs like Ozempic for seniors... all the insurance companies had to do was say 'yes,' and they refused."

Chuck Flint says that this refusal forces the government into more expensive workarounds that ultimately hurt seniors' health and increase the burden on American taxpayers.